Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia.
BACKGROUND
Recent reports have suggested that high-density lipoprotein (HDL) is metabolically related to glucose metabolism and renal function. Statin administration clinically increases HDL cholesterol (HDL-C).


OBJECTIVE
To confirm that change in HDL-C by statin switching is associated with glucose metabolism and renal function in hypercholesterolemic patients.


METHODS
In hypercholesterolemic outpatients (n = 129) who had taken either statin, as atorvastatin, pitavastatin, or rosuvastatin and switched to another statin, the relationship of change in HDL-C to glycated hemoglobin and estimated glomerular filtration rate (eGFR) was assessed.


RESULTS
Change in HDL-C did not significantly correlate with change in HbA1c, eGFR calculated from creatinine (eGFRcre), and eGFR calculated from cystatin C (eGFRcys). The subjects were then divided into 2 groups by change in HDL-C: no change or decrease in HDL-C (HD group) and increase in HDL-C (HI group). In the HI group, apolipoprotein A-1 (Apo A-1) and eGFRs were significantly increased by statin switching. There were significant differences in changes in HDL-C, Apo A-1, lipoprotein lipase, glycated hemoglobin, and eGFR calculated from creatinine between the groups. In the patients with impaired glucose tolerance or diabetes, change in HbA1c was also significant between the groups.


CONCLUSIONS
Our data suggest that an increase in HDL-C due to statin switching is associated with improvement in glucose metabolism and renal function.
Kakuda Clinic, Kahoku, Ishikawa, Japan. Electronic address: hirkakud@yahoo.co.jp.
Hirokazu
H
Kakuda
Matoba Clinic, Kanazawa, Ishikawa, Japan.
Munetoshi
M
Matoba
Nakatoh Clinic, Kanazawa, Ishikawa, Japan.
Hideaki
H
Nakatoh
Nagao Clinic, Hakusan, Ishikawa, Japan.
Shin
S
Nagao
Division of Cardiology, Kanazawa Medical University, Ishikawa, Japan.
Noboru
N
Takekoshi
D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology*; D008297:Male
D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005947:Glucose
Glucose metabolism; HDL cholesterol; Renal function; Statin